Anthrax is an infection caused by the spore-forming bacterium, Bacillus anthracis. Infection occurs in mammals, particularly herbivores that ingest bacterial spores from soil. Human infection occurs from inhalation of spores, ingestion of animal meat contaminated with spores, or percutaneous inoculation of spores from exposure to infected animals or contaminated animal products. Anthrax has been an occupational disease of textile workers, farmers, butchers, veterinarians, and shepherds.


Protective Antigen Bacillus Anthracis Lethal Toxin Edema Factor Anthrax Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Turnbull PCB. Introduction: Anthrax history, disease and ecology. Curr Top Microbiol Immunol 2002; 271: 1–19.PubMedGoogle Scholar
  2. 2.
    Grabenstein JD. Anthrax vaccine: A review. Immunol Allergy Clinics North Am 2003; 23: 713–730.CrossRefGoogle Scholar
  3. 3.
    Irmak H, Buzgan T, Karahocagil MK, et al. Cutaneous manifestations of anthrax in Eastern Anatolia: A review of 39 cases. Acta Med Okayama 2003; 57: 235–240.PubMedGoogle Scholar
  4. 4.
    Dixon TC, Meselson M, Guillemin J, Hanna PC. Anthrax. New Engl J Med 1999; 341: 815–826.PubMedCrossRefGoogle Scholar
  5. 5.
    Watson A, Keir D. Information on which to base assessments of risk from environments contaminated with anthrax spores. Epidemiol Infect 1994; 113: 479–490.PubMedCrossRefGoogle Scholar
  6. 6.
    Chensue SW. Exposing a killer: Pathologists angle for anthrax. Am J Pathol 2003; 163: 1699–1702.PubMedGoogle Scholar
  7. 7.
    Moayeri M, Leppla SH. The roles of anthrax toxin in pathogenesis. Curr Opin Microbiol 2004; 7: 19–24.PubMedCrossRefGoogle Scholar
  8. 8.
    Brook I. The prophylaxis and treatment of anthrax. Int J Antimicrob Agents 2002; 20: 320–325.PubMedCrossRefGoogle Scholar
  9. 9.
    Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994; 266: 1202–1208.PubMedCrossRefGoogle Scholar
  10. 10.
    Inglesby TV, O’Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002: Updated recommendations for management. JAMA 2002; 287: 2236–2252.PubMedCrossRefGoogle Scholar
  11. 11.
    Cinti SK, Saravolatz L, Nafziger D, Sunstrum J, Blackburn G. Differentiating inhalational anthrax from other influenzalike illnesses in the setting of a national or regional anthrax outbreak. Arch Intern Med 2004; 164: 674–676.PubMedCrossRefGoogle Scholar
  12. 12.
    Stephenson J. Rapid anthrax test approved. JAMA 2004; 292: 30.PubMedCrossRefGoogle Scholar
  13. 13.
  14. 14.
    Lebowich RJ, McKillip BG, Conboy JR. Cutaneous anthrax: A pathologic study with clinical correlation. Am J Clin Pathol 1943; 13: 505–515.Google Scholar
  15. 15.
    Mallon E, McKee PH. Extraordinary case report: Cutaneous anthrax. Am J Dermatopathol 1997; 19: 79–82.PubMedCrossRefGoogle Scholar
  16. 16.
  17. 17.
    Kaya A, Tasyaran MA, Erol S, Ozkurt Z, Ozkan B. Anthrax in adults and children: A review of 132 cases in Turkey. Eur J Clin Microbiol Infect Dis 2002; 21: 258–261.PubMedCrossRefGoogle Scholar
  18. 18.
    Karginov VA, Robinson TM, Riemenschneider J, et al. Treatment of anthrax infection with combination of ciprofloxacin and antibodies to protective antigen of Bacillus anthracis. FEMS Immunol Med Microbiol 2004; 40: 71–74.PubMedCrossRefGoogle Scholar
  19. 19.
    Bast DJ, Athamna A, Duncan CL, et al. Type II topoisomerase mutations in Bacillus anthracis associated with high-level fluoroquinolone resistance. J Antimicrob Chemother 2004; 54: 90–94.PubMedCrossRefGoogle Scholar
  20. 20.
    Kenney RT, Yu J, Guebre-Xabier M, et al. Induction of protective immunity against lethal anthrax challenge with a patch. J Infect Dis 2004; 190: 774–782.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Personalised recommendations